New antibody drug takes on tough blood cancers
NCT ID NCT05787496
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial tested a new drug called NC525 in people with advanced myeloid neoplasms, including relapsed or refractory acute myeloid leukemia. The main goal was to check safety and tolerability, with a secondary focus on whether the drug could shrink tumors or improve survival. The study was terminated after enrolling 28 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NC525 (a monoclonal antibody targeting LAIR-1)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced blood cancers that have not responded to other therapies.
What could go wrong
This is a very early Phase 1 trial focused on safety, so it is unknown if NC525 will effectively treat the disease. The trial was terminated, meaning results may be limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
City of Hope
Duarte, California, 91010, United States
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University of Miami
Miami, Florida, 33136, United States
-
Washington University School of Medicine in St. Louis
St Louis, Missouri, 63110, United States
-
Weill Cornell Medicine
New York, New York, 10022, United States